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Abstract: Cardiac insulin signaling can be impaired due to the altered fatty acid metabolism to
induce insulin resistance. In diabetes and insulin resistance, the metabolic, structural and ultimately
functional alterations in the heart and vasculature culminate in diabetic cardiomyopathy, coronary
artery disease, ischemia and eventually heart failure. Glucolipotoxicity describes the combined, often
synergistic, adverse effects of elevated glucose and free fatty acid concentrations on heart structure,
function, and survival. The quality of fatty acid shapes the cardiac structure and function, often
influencing survival. A healthy fatty acid balance is therefore critical for maintaining cardiac integrity
and function.
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1. Introduction
Glucotoxicity was first described in the islets and defined as non-physiological and potentially
permanent β-cell damage due to persistent hyperglycemia [1] but it is also implicated in the
pathogenesis of cardiovascular disease (CVD). Chronic hyperglycemia modulates the expression of
multiple key glucotoxic proteins [2] thereby disrupting intracellular signal transduction by altering
kinase C protein activity, generating reactive oxygen species (ROS), activating endoplasmic reticulum
(ER)-stress, generating advanced glycation end products (AGEs), activating the polyol pathway and
hexosamines, and increasing proinflammatory cytokine and growth factor release [2–4]. These metabolic
derangements contribute to endothelial dysfunction that may progress to atherosclerosis [2–4].
Fatty acids (FAs) are essential substrates for energy production, and individual FAs induce various
multiple signaling pathways for cellular function [5]. FA overload may damage the myocardium
through high FA β-oxidation and toxic lipid species accretion in the myocardium [5] presenting
lipotoxicity [6]. Excess lipids, or their metabolites and derivatives, in organs, i.e., lipotoxicity, impair
insulin signaling and activate hepatic, skeletal muscle and cardiac inflammation. Insulin resistance is
intrinsically linked to a dysregulated FA metabolism [7].
Glucolipotoxicity refers to the combined, often synergistic deleterious actions of elevated
glucose and free fatty acid (FFA) concentrations on β-cell physiology and survival [8–10] that can
be extended to other organs such as the heart. Obesity prompts inflammation, insulin resistance,
hyperleptinemia, elevated circulating FFA and triglyceride concentrations, and hypertension [11].
These compromised metabolic states, in conjunction with a high saturated fat diet and high glycemic
load, elicit deleterious cardiac effects characterized by the myocardial accumulation of toxic glucose and
lipid intermediates [11]. Further, these metabolic derangements can trigger cardiomyocyte apoptosis,
fibrosis, cardiomyocyte hypertrophy, mitochondrial dysfunction, and impaired systolic and diastolic
function that ultimately lead to heart failure [11]. Hence, glucolipotoxicity compromises cardiac
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structure and function that may induce CVD. Therefore, physiological glucose and lipid concentrations
are required to maintain cardiac integrity and function.
2. Cardiac Development, Bioenergetics, and Physiology
During fetal development, the heart, pancreas, and liver are highly sensitive to maternal body
composition fluctuations prior to conception and/or during early gestation. Maternal obesity and
dysregulated metabolism induce fetal visceral fat deposition, thereby increasing the offspring’s
susceptibility to metabolic disease later in life [12]. Overall, the degree of pre-gestation maternal
overfeeding and adiposity determine the fetal overgrowth trajectory and mid-gestational fetal organ
development, with milder maternal adiposity inducing minor changes [13].
Adult hearts have a low regenerative potential [14,15], therefore, the loss of cardiac muscle
through ischemic injury (myocardial infarction) far exceeds the cardiac regenerative capacity for
new cardiomyocytes [16]. The subsequent cardiomyocyte deficit, ~one billion cells [16], markedly
weakens cardiac pump function that progresses to cardiac failure [17]. Therefore, it is critical that
heart development is optimal to provide the structure to enable function, particularly upon metabolic
challenges later in life.
Early heart growth is accompanied by mononucleated cardiomyocyte proliferation [18]. By mid-
gestation, these mononucleated cardiomyocytes develop into binucleated cardiomyocytes thereby
enhancing cardiac mass by hypertrophy [19,20]. In humans and sheep, adult cardiomyocyte
endowment is largely determined prior to birth [21]. Positive influences to enable optimal heart
development and growth during fetal life is critical. Any insult, such as high-fat feeding with exposure
to excess harmful FAs, such as saturated FAs, and glucose, may impair fetal heart development that is
exacerbated by maternal obesity.
The heart has high energy demands. In fetal hearts, glucose and lactate are the primary energy
sources, whereas postnatally, FA β-oxidation provides energy [22–24]. Gestational diabetes, persistent
hyperglycemia, and hyperlipidemia all contribute to shaping heart development, structure, and
function. Glucose is the primary energy source for fetal cardiomyocytes likely attributed to limited
circulating FA availability or immature enzyme systems [18]. Cardiomyocyte maturation may be
linked to cardiac metabolism but is dependent on several factors that influence cardiac maturation
and metabolism [18]. Glucocorticoids are required in late gestation for fetal organ system maturation
such as the heart, lung, and gut [25]. The fetal cardiac glucose uptake is facilitated through the
insulin-independent glucose transporter type 1 (GLUT1) [26] with anaerobic glycolysis largely meeting
the ATP demands [27]. However, with no continuous placental nutrient supply shortly after birth,
the circulating oxygen supply rapidly increases to drive mitochondrial ATP production to maintain
cardiac energy demands over the life course [28]. These events coincide with the shift to FA β-oxidation
as the dominant ATP provider in normal resting adult hearts [23].
Human hearts have high-energy demands with a daily ATP turnover of ~30 kg [29]. Thus, the heart
requires a high oxygen uptake to generate sufficient ATP by oxidative phosphorylation for proper
function [30]. Cardiac diseases are characterized by an altered myocardial energy metabolism [30].
A general decrease in oxidative capacity and down-regulation of FA β-oxidation enzymes in cardiac
muscle were observed in heart failure [28,31–35]. In diabetic patients, mitochondria in the heart had
decreased FA-supported respiratory capacity and a reduced capacity to oxidize palmitoylcarnitine [36].
This was confirmed in the mitochondria of obese and diabetic mice with reduced oxidative capacity [37].
Further, there is a reduction in both FA β-oxidation genes and enzyme expression profiles, and reduced
myocardial energy generation in human and animal heart failure [31–35]. In addition, insulin resistance
may be associated with incomplete FA β-oxidation, thereby yielding an increase in acylcarnitines [38].
In primary myotubes, a reduction of short-chain acylcarnitine and acetylcarnitine formation was
reported to protect against palmitate-induced insulin resistance [38]. The decrease in FA-supported
respiration may result in an increase in incomplete FA β-oxidation and the subsequent increase in
short-chain acylcarnitines, likely linked to the onset of insulin resistance [30].
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In humans and rats, an increase in dietary fat saturation contributed to higher systolic and
diastolic blood pressure [39,40]. In rats, high omega-6 FA diets have antihypertensive effects on
angiotensin (Ang) II-induced hypertension [41]. FA quality, therefore, influences cardiac function.
An Ang II-induced increase in left ventricular c-fos mRNA expression was higher in high-fat diet
(HFD) fed rats fed but not altered in polyunsaturated FA fed rats [42]. The quality of dietary fat alters
early hypertrophic gene activation in the pressure-overloaded myocardium and requires the activation
of the activator protein 1 (AP1) and mitogen-activated protein kinases (MAPK) signal transduction
pathways [43]. The quality of fat also shapes the cardiac structure through activating and altering
cardiac-specific factors. A diet with an adequate mix of FAs, high in beneficial FAs and low in harmful
FAs, is required for maintaining cardiac health.
Adult diabetic cardiomyopathy may involve an irregular cardiac metabolism and subsequently
lead to oxidative stress, mitochondrial dysfunction, and mitophagy [44–47]. Cellular bioenergetics
play increasingly key roles in maintaining health and in the pathogenesis of disease [48], particularly
the heart [49]. Due to hearts’ high-energy requirements, a continuous fuel supply is required to
sustain perpetual contractile activity, thereby rendering it susceptible to failure in the presence of
any metabolic and/or mitochondrial derangements [28]. In adults, the normal resting hearts’ energy
demands are primarily sustained by FAs [23,46,50,51]. Despite a FA preference, the hearts can use
different substrates dependent on supply and demand [12]. This fuel flexibility enables continuous
energy production under varying metabolic states such as developmental maturation, starvation (fuel
supply), exercise (fuel demand), and ischemia (oxygen supply) [28,50,52]. Diminished fuel flexibility
from excess circulating fuels, such as glucose and FAs, and compromised metabolic states, such as
insulin resistance, predisposes to heart failure [46,49].
The adverse cardiovascular effects of obesity (such as cardiomyocyte FA overload) likely
encompasses arrhythmias, cardiomyopathy, and heart failure [53,54]. The normal heart attains ≥60%
of its energy requirements from long-chain FA β-oxidation to yield ATP [55]. Cardiac hypertrophy is
linked to the suppression of myocardial FA β-oxidation with the reversion of increased glucose
utilization [55,56], suggesting an association of altered myocardial FA metabolism and cardiac
hypertrophy. In neonatal ventricular cardiomyocytes, long-chain FAs were observed to alter Ang
II-induced hypertrophic responses [57]. In vivo, prolonged dietary FA intake also influences the
progression to left ventricular hypertrophy [58–62], which reflects cardiac remodeling in response to
the FA intake.
3. Postnatal Cardiac Insulin Signaling and Insulin Resistance
Postnatally, GLUT4 regulates the cardiac glucose uptake through the insulin signaling pathway
viz., the insulin receptor (IR), insulin receptor substrate-1 (IRS1), phosphatidylinositol 3-kinase (PI3K),
3-phosphoinositide-dependent protein kinase 1 (PDPK1) and/or Akt [18] although different insulin
signaling factor isoforms and types may be activated to achieve cardiac glucose uptake. PDPK1
activation induces atypical protein kinase C zeta (PKCζ) phosphorylation and activation, whereas
Akt phosphorylation induces Akt substrate 160 kDa (AS160) phosphorylation and activation [18].
Phosphorylated PKCζ and AS160 are both integral for GLUT4 translocation to plasma membranes for
glucose uptake [63].
Despite insulin resistance being a great predictor for CVD, it is rarely the sole contributor to
the disease in patients [64]. In diseased states, such as diabetes and insulin resistance, the metabolic,
structural and ultimately functional alterations in the heart and vasculature culminate in diabetic
cardiomyopathy, coronary artery disease, ischemia and eventual heart failure [65,66]. The impairment
of insulin-stimulated glucose uptake is the first and steadiest alteration that occurs in the hearts of
animal models in the insulin resistance evolution [67]. This change occurs prior to defects in insulin’s
capacity to stimulate or elevate PI3K/Akt signaling, and is attributed to the GLUT4 protein reduction
in combination with an impairment of GLUT4 membrane translocation.
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The development of hyperinsulinemia and insulin resistance in murine cardiac hypertrophy is due
to the pressure overload boosts in myocardial insulin signaling to Akt (in excess) which adds to the left
ventricular reconstruction at an accelerated level and ultimately, a shift to heart failure [68]. The heart
responds to insulin, and insulin resistance is a prominent defect in individuals who suffer from diabetes,
obesity and metabolic syndrome [69,70]. HF feeding often triggers obesity, insulin resistance, metabolic
syndrome, diabetes, and CVD. In mice, HFD-induced myocardial insulin resistance was established
within ten days [71]. There was also an association between insulin resistance and decreased glucose
uptake in the myocardium, reduced PKB/Akt activity and reduced GLUT4 levels that preceded and
was independent of systemic insulin resistance [71].
In myocardial insulin resistance, the rate of FA β-oxidation remains normal or may be
increased, but the rate of glucose oxidation is usually decreased whether insulin-stimulated or
non-insulin-stimulated [72]. ROS are free radicals and by-products of reduction-oxidation reactions
under physiological conditions in eukaryotic cells [73]. Progeny from nutrient-limited rat dams
developed hypertension concomitant with elevated oxidative stress in mesenteric arterioles. Further,
apart from vascular dysfunction, intrauterine growth restriction (IUGR) promoted ROS-mediated
cardiac damage [74]. An increase in the lipid uptake and its subsequent oxidation, e.g., as in insulin
resistance, can give rise to cellular lipid intermediate accumulation, excess mitochondrial or peroxisome
ROS production, and cardiac derangements, leading to dysfunction [72]. This was demonstrated
by the over-expression of cardiac-specific peroxisome proliferator-activated receptor alpha (PPARα)
that induced increased cardiac lipid oxidation, deranged metabolism and subsequently led to both
structural and functional alterations detrimental to the heart [65]. The induction of insulin resistance in
mice by exposure to a HFD also triggered the reconstruction of the heart and systolic dysfunction [71].
The heart’s ability to tolerate and withstand ischemia and reperfusion can be constrained by myocardial
insulin resistance by reducing the glucose uptake as well as the synthesis of glycogen and glycolysis,
all which contribute to ATP delivery in the ischemic heart for cellular metabolism [75].
4. Postnatal Cardiac Fatty Acid Signaling
Cardiac FA uptake is facilitated by fatty acid translocase (FAT/CD36) and fatty acid transport protein
1 (FATP1) [76]. However, FA β-oxidation is regulated by adiponectin receptor 1 (AdipoR1) activation
through adiponectin binding, leading to AMP-activated protein kinase (AMPK) phosphorylation and
activation that subsequently phosphorylates acetyl CoA carboxylase (ACC) [77,78]. ACC catalyzes
malonyl CoA production, thereby inhibiting carnitine palmitoyltransferase-1 (CPT1) from enabling FA
transport into the mitochondria [79]. Peroxisome proliferator-activated receptor gamma coactivator
1 alpha (PGC1α) and peroxisome proliferator-activated receptor alpha (PPARα) both also regulate
cardiac FA β-oxidation, thereby stimulating mitochondrial biogenesis and FA β-oxidation via increased
transcription of regulators such as CPT1 [80]. Pyruvate dehydrogenase kinase-4 (PDK4) helps promote
cardiac FA β-oxidation through glucose oxidation inhibition (via pyruvate dehydrogenase complex
inhibition) [81]. However, during late gestation in fetal sheep, the activation of the insulin growth factor
2 receptor (IGF2R) signaling induces cardiac hypertrophy [82], evident by the atrial natriuretic peptide
(ANP) overexpression [83].
Cardiac bioenergetics differs during fetal and postnatal life (Table 1). In the fetal heart, glucose
transport through GLUT1 is insulin-independent and meets the ATP requirements through anaerobic
glycolysis. In the developed heart, FAs primarily meet the heart’s energy requirements through
FA β-oxidation. Should an alternative fuel source be required in states of high energy demands or
low FA availability, insulin-dependent glucose is transported into the heart through GLUT4. In the
developed heart, cardiac FA uptake is facilitated by FAT/CD36 and FATP1, with both FA transporters
also localized in the fetal heart. In the fetal heart, although insulin signaling may be altered due to
insults (e.g., high-fat programming where the heart is exposed to excess FAs during development),
overt insulin resistance does not present but may manifest later in life. In the developed heart
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with cardiac insulin resistance, the rate of glucose oxidation is usually decreased (independent of
insulin-stimulation), whereas the rate of FA β-oxidation remains normal or may be increased.
Table 1. The fetal and postnatal cardiac glucose and fatty acid utilization.
Fetal Heart Developed Heart
Main fuel source Glucose Fatty acids
Glucose transport GLUT1 GLUT4
Insulin dependency Insulin-independent Insulin-dependent
Meeting energy demand Anaerobic glycolysis Fatty acid β-oxidation
Cardiac fatty acid uptake FAT/CD36; FATP1 FAT/CD36; FATP1
Cardiac insulin resistance:
glucose oxidation - Decreased
Cardiac insulin resistance:
fatty acid oxidation - Normal or increased
Cardiac glucose and fatty acid utilization in the fetal and developed heart varies in substrate and transport preference.
In cardiac insulin resistance, glucose oxidation is decreased whereas fatty acid oxidation is normal or increased.
5. High Fat Diets and Fatty Acids Alter Cardiac Gene Expression Involved in Hypertrophy
Several inherited FA metabolism disorders are characterized by cardiac hypertrophy and
cardiomyopathy [84]. Given that FAs are the mature heart’s primary energy source and that decreased
FA utilization is implicated in the onset of cardiac hypertrophy [55], dietary FA supplementation may
impact early hypertrophic processes and activate cardiac genes expressed during pressure overload [43].
This was reported in a study where excess feeding of saturated or polyunsaturated FAs was shown to
distinctly modify the expression of the hypertrophy-associated genes ANP, B-type natriuretic peptide
(BNP), and skeletal α-actin in response to Ang II-induced pressure overload [43]. In rats maintained
on high linoleic acid (an omega-6 FA), Ang II exerted a marked increase in ANP, BNP, and skeletal
α-actin mRNA expression relative to maintenance on a high saturated fat diet [43]. Thus, different fat
classes elicit variable effects on cardiac gene expression that influence cardiac hypertrophy that may
also be dependent on the timing and duration of the dietary administration.
6. Cardiac Glucolipotoxicity
6.1. Cardiac Bioenergetics in Cardiovascular Disease
The metabolic milieu informs the cardiac metabolic adaptation for the conversion of energy from
many oxidizable substrates to sustain contractile energy needs [11]. In heart failure, the ATP turnover
rate reduces, whereas the substrate uptake rate may not reduce proportionally [11]. Thus, an imbalance
in cell-substrate availability and intracellular substrate oxidation with the ensuing accumulation of
intermediates derived from glucose and FA metabolism presents a vicious cycle [11]. When FA uptake
surpasses fat oxidation capacity, the lipid overload prompts an increase in the triglyceride storage
and lipid metabolite accumulation (especially ceramides), concomitant with higher oxidative and ER
stress [85], and lipid-induced membrane function modifications [11].
6.2. Diabetes and Cardiovascular Disease
Diabetes and CVD are intrinsically linked. Diabetes increases CVD risk, exacerbated by coexistent
hypertension [86]. Causal mechanisms that induce microvascular and macrovascular diabetic
complications such as oxidative stress, inflammation, and fibrosis, also induce vascular remodeling
and dysfunction in hypertension [86]. In diabetes and hypertension, augmented vascular oxidative
stress induces post-translational oxidative protein alterations prompting cellular damage and vascular
dysfunction [86]. In diabetic and obese adults, elevated circulating glucose and FA concentrations,
and compromised insulin activity may contribute to diabetic cardiomyopathy [12]. In adult diabetic
cardiomyopathy, first diastolic then systolic dysfunction, cardiac hypertrophy, and heart failure are
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often present without the influence of additional cardiovascular risk factors [44,45]. In some obese
diabetic patients, cardiomyopathy presents as characterized by contractile dysfunction specific to
cardiac muscle [87–90]. In obese and diabetic rodents, the onset of cardiomyopathy includes diastolic
dysfunction [91,92], cardiomyocyte hypertrophy [93–95], interstitial fibrosis [93,96,97], early-onset
metabolic maladaptation [94,95,98,99], and progressive lipid accumulation [94,95], all precursors to
heart failure [100]. Cardiomyopathy is typically accompanied by metabolic inflexibility attributed
to an insulin deficiency or impaired action thereby causing hyperglycemia; hypergycemia with the
overconsumption of harmful FAs, represent precursors to glucolipotoxicity [11,87,101,102].
6.3. The Obesity Paradox
Some obese individuals do not present with CVD. Although obesity increases CVD [103],
obese patients who recover from heart failure and acute myocardial infarction have improved
survival outcomes which describes the obesity paradox [104]. The obesity paradox is influenced
by comorbidities, confounders, selection (or survival) bias, and the utilization of body mass index
(BMI) for weight classification [103]. Comorbidities include CVD and diabetes. For confounding
factors, smoking is linked to reduced BMI and increased mortality [103]. Selection bias arises in obese
patients with an earlier onset of disease or untimely death which excludes them from studies [103].
BMI does not account for body composition, fat distribution, fat and lean mass, all factors that may
influence CVD risk [103]. Waist circumference combined with BMI is a better proxy for identifying
obese individuals predisposed to CVD [103]. The obesity paradox is complex and requires further
elucidation. However, when obese individuals remain in their compromised metabolic state, which
is exacerbated by the persistent consumption of unhealthy diets and leading inactive lifestyles, they
become more susceptible to CVD.
6.4. Cardiac Lipotoxicity and Cardioprotection
The quality of fat determines shifts to cardiac lipotoxicity or cardioprotection. For example,
excess saturated FA intake would impose cardiac lipotoxicity whereas optimal omega-3 FA intake
would confer cardioprotection. A high saturated fat diet has adverse effects on cardiovascular health.
Dietary saturated FAs, compared to polyunsaturated FAs such as omega-3 FAs, increase circulating
low-density lipoprotein cholesterol (LDL-C), which enhances the susceptibility to coronary heart
disease [105]. Further, specific saturated FAs variably modify plasma lipoprotein concentrations,
with each saturated FA (excluding stearic acid) inducing an increase in LDL- and high-density
lipoprotein cholesterol (HDL-C) concentrations with a reduction in triglyceride concentrations [105].
Dietary saturated FA intake should be <10% of the total caloric intake [106] as reducing dietary
saturated FAs lowered cardiovascular events by 17% [107] with each 5% increase in the saturated
FA intake linked to an 8% increase in the risk for mortality [108]. Replacing saturated FAs with
polyunsaturated FAs, such as omega-3 FAs, lowers the mortality risk from CVD [108]. High omega-3
FA consumption, especially docosahexaenoic acid and eicosaehexanoic acid, protects against CVD
through decreasing circulating triglyceride concentrations, inflammation, and lethal arrhythmias,
also enhancing mitochondrial function and remodeling membranal phospholipids [109]. Therefore,
beneficial omega-3 FAs should be considered to replace saturated FAs, the latter which are harmful in
excess, to confer some cardioprotection in patients with CVD.
6.5. Gluco-, Lipo- and Glucolipotoxicity
Persistent hyperglycemia presents glucotoxicity whereas continuous exposure to harmful FAs
presents lipotoxicity. Where both glucotoxicity and lipotoxicity coexist, often in obesity, insulin
resistance, diabetes and CVD, glucolipotoxicity often triggers synergistic adverse metabolic outcomes.
Chronic overconsumption of fat and carbohydrates (e.g., glucose) elevates circulating insulin, leptin,
FFA and triglyceride concentrations, with or without diabetes, thereby exposing the heart to toxic
anabolic stimuli and an overabundance of oxidative substrates [11]. Chronic increased insulin demand,
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e.g., obesity, insulin resistance, β-cell dysfunction and diabetes, predisposes to the onset of metabolic
disease [104] that includes adverse cardiac outcomes and CVD. Chronic HF feeding is linked to the
etiology of obesity, insulin resistance, β-cell dysfunction [104], diabetes and CVD. A constant increase
in FFA or saturated FA intake from a HFD may trigger adipogenesis thereby contributing to obesity,
an altered inflammatory response, insulin resistance, metabolic syndrome [105,106], diabetes and
CVD. Therefore, there is a close association between diabetes and CVD through HF consumption, i.e.,
increased harmful FA intake (e.g., saturated FAs) and hyperglycemia through glucolipotoxicity.
There is consensus that prolonged cardiac exposure to excess circulating fuels (e.g., glucose,
FFAs, and triglycerides) and growth hormones (e.g., insulin and leptin) speed up myocardial
pathology that leads to cardiac hypertrophy and failure [11]. Both elevated circulating glucose
and FFAs have deleterious effects on health outcomes through glucolipotoxicity. Tissue-specific
cellular damage, induced by ROS, has been observed with excess glucose and FFA exposure [107–109],
resulting in glucolipotoxicity-induced oxidative stress, a driver of apoptosis [110]. There is elevated
oxidative stress in uncontrolled diabetes and potentially in the evolution of β-cell and cardiomyocyte
dysfunction in diabetes [111–113]. High glucose in combination with the saturated FA, palmitic acid,
consistently caused cardiomyoblast apoptosis [110]. In vitro, hyperglycemia and high palmitic acid
exposure induced apoptosis and increased intracellular ROS levels in rat heart myoblast cells (H9c2),
suggesting that glucolipotoxicity-induced cardiomyocyte apoptosis was triggered by intracellular ROS
generation [110]. The heart’s impaired ability to oxidize fat and carbohydrates prompts non-oxidative
metabolic intermediate and ROS accumulation [71]. In humans, this dysregulated fuel metabolism
also presents in obesity, diabetes, and heart failure [114].
Cardiomyocyte glucolipotoxicity primarily originates or terminates in the mitochondria and the
ER [112,115–118]. In cardiomyocyte glucolipotoxicity, protein quality control is impaired, resulting
in ER stress and activation of the protein degradation pathway [119,120]. Chronic glucolipotoxicity
aggravates ER stress, saturates and impairs proteasomal protein degradation, thereby resulting in
toxic misfolded protein accumulation [121,122]. In obesity and diabetes, glucolipotoxicity precedes
diabetic cardiomyopathy [95,96,99,100,114], inferring that cardiac glucolipotoxicity may induce
cardiomyocyte dysfunction [101]. Further, in obese diabetic hearts, glucolipotoxicity limits autophagy
and macroautophagy, linked to insufficient transcriptional regulation by transcription factor EB
(TFEB) [101]. The TFEB content loss through glucolipotoxicity may be attributed to increased TFEB
inhibitory phosphorylation thereby preventing TFEB nuclear translocation to activate coordinated
lysosomal enhancement and regulation (CLEAR) genes for lysosomal autophagic and functional
maintenance [101]. The inhibition of TFEB impairs the lysosome function causing proteotoxicity,
ER stress, mitochondrial dysfunction, and cell death thereby predisposing obese diabetic hearts to
cardiomyopathic failure [101]. Saturated FAs alone influence TFEB regulation, exacerbated by elevated
glycemia [101] reflecting glucolipotoxicity. Palmitate myocyte overloading (but not oleate) diminished
cellular TFEB and impaired autophagy, inferring that TFEB regulation and cardiomyocyte autophagy is
dependent on the FA type [101]. Glucolipotoxicity-induced TFEB content reduction was also observed
in class 1 obese patients’ hearts [101]. Thus, with glucolipotoxicity, lysosomal autophagic suppression
was linked to a decreased lysosomal content, reduced activity of cathepsin-B, and decreased cellular
TFEB content, thereby increasing the myocytes’ vulnerability to cardiac injury [101].
6.6. Glucolipotoxicity Shapes Cardiac Outcomes
In the fetal heart, glucotoxicity and lipotoxicity coexist resulting in glucolipotoxicity that induces
fetal hyperinsulinemia [12]. Fetal hyperinsulinemia adversely affects the developing fetal heart
(Figure 1). In the developed heart, glucotoxicity alters the cardiac protein expression, resulting in
an increase in ROS, ER stress and advanced glycation end products (AGEs) that triggers endothelial
dysfunction and atherosclerosis (Figure 1). Hyperglycemia accelerates AGE formation, AGEs
accumulate in blood vessels and subsequently induce cardiovascular damage triggered in advanced
diabetes [123]. AGEs stimulate ROS generation, which in turn further enhances AGE formation [123].
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In addition, hyperglycemia prompts redox-sensitive protein kinase C, polyol and hexosamine pathway
activation, thereby exacerbating mitochondrial dysfunction, oxidative stress, ER stress, and cellular
damage [124–128]. Oxidative stress is linked to reduced nitric oxide (a vasodilator) bioavailability
thereby inducing endothelial dysfunction [86]. Lipotoxicity increases inflammation, reduces insulin
signaling and dysregulates the FA metabolism resulting in cardiac insulin resistance (Figure 1).
Glucolipotoxicity increases both toxic glucose and lipid myocardial intermediates which collectively
alters the cardiac structure evident by cardiomyocyte hypertrophy and apoptosis, and fibrosis
concomitant with mitochondrial dysfunction and compromised the systolic and diastolic function,
which ultimately precede heart failure (Figure 1).
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7. Future Directions
Future research should focus on defining the proper healthy FA balance throughout different life
stages and different states of metabolic disease to support a healthy heart. For example, glucose is
the main energy supplier for the developing heart and essential FAs are required for optimal growth
and for the development of organs including the heart. Hence, defining the optimal glucose and
FA balance during fetal life is critical for normal cardiovascular development and function. Further,
obesity, insulin resistance, and diabetes may co-present with CVD which will require more precise
treatment based on individual treatment needs. Cardiac glucolipotoxicity should be investigated in
the context of cardioprotection given that diverse populations with different genetic constitutions and
environmental situations will be variably affected by a nutritional cardiac insult e.g., saturated FAs,
and respond differently to a nutritional cardioprotective agent, e.g., omega-3 FAs.
8. Conclusions
Glucolipotoxicity induces adverse cardiac outcomes, highlighting the importance of physiological
glycemia and lipidemia to maintain a healthy heart. The quality of FA shapes cardiac structure and
function, often influencing survival. A healthy FA balance is therefore critical for maintaining cardiac
integrity and function.
Author Contributions: M.E.C. was responsible for the conception and revision of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The author declares no conflict of interest.
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